세계의 게노믹스 파트너링 조건과 합의(2014-2020년)
Global Genomics Partnering Terms and Agreements 2014 to 2020
상품코드 : 939923
리서치사 : Current Partnering, a division of Wildwood Ventures Limited
발행일 : 2020년 06월
페이지 정보 : 영문 550+ Pages
US $ 3,495 ₩ 4,001,000
PDF by E-mail (Single User License)
US $ 5,245 ₩ 6,005,000
PDF by E-mail (Multi User License - 2 to 5 Users)
US $ 10,495 ₩ 12,015,000
PDF by E-mail (Single Site License - 6+ Users)
US $ 17,495 ₩ 20,030,000
PDF by E-mail (Global License)


한글목차

세계의 게노믹스 관련 시장에서 제휴 계약의 동향과 조건에 대해 조사분석했으며, 최근 동향, 대표적인 거래의 개요, 활발한 사업자, 제휴 계약 디렉토리, 주요 거래(금액별) 등에 관한 정보를 정리하여 전해드립니다.

목차

개요

제1장 서론

제2장 게노믹스 관련 계약 동향

제3장 주요 게노믹스 관련 거래

제4장 가장 활발한 게노믹스 관련 사업자

제5장 게노믹스 관련 계약 디렉토리

제6장 게노믹스 관련 계약 : 기술 유형별

제7장 제휴 리소스 센터

부록

KSA 20.06.17
영문 목차

영문목차

‘The Global Genomics Partnering Terms and Agreements 2014 to 2020 report’ provides comprehensive understanding and unprecedented access to the Genomics partnering deals and agreements entered into by the worlds leading healthcare companies.

‘The Global Genomics Partnering Terms and Agreements 2014 to 2020 report’ provides an understanding and access to the Genomics partnering deals and agreements entered into by the worlds leading healthcare companies.

‘The Global Genomics Partnering Terms and Agreements report’ provides an understanding and access to the Genomics partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter Genomics partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors Genomics technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains links to online copies of actual Genomics deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:

The initial chapters of this report provide an orientation of Genomics dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Genomics dealmaking since 2014, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Genomics deals since 2014. Deals are listed by headline value, signed by big pharma, most active Genomics dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Genomics dealmaking with a brief summary followed by a comprehensive listing of Genomics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of Genomics partnering deals signed and announced since Jan 2014, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of Genomics partnering deals signed and announced since Jan 2014. The chapter is organized by specific Genomics technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by Genomics partnering company A-Z, deal type definitions and Genomics partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Genomics partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Genomics technologies and products.

Report scope

‘Global Genomics Partnering Terms and Agreements 2014 to 2020’ is intended to provide the reader with an in-depth understanding and access to Genomics trends and structure of deals entered into by leading companies worldwide.

‘Global Genomics Partnering Terms and Agreements 2014 to 2020’ includes:

In ‘Global Genomics Partnering Terms and Agreements 2014 to 2020’, the available contracts are listed by:

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Benefits

‘Global Genomics Partnering Terms and Agreements 2014 to 2020’ provides the reader with the following key benefits:

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Genomics dealmaking

Chapter 3 - Leading Genomics deals

Chapter 4 - Most active Genomics dealmakers

Chapter 5 - Genomics contracts dealmaking directory

Chapter 6 - Genomics dealmaking by technology type

Chapter 7 - Partnering resource center

Appendices

Table of figures

(주)글로벌인포메이션 02-2025-2992 koreainfo@gii.co.jp
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기